The TheraP trial (NCT03392428) showed that LuPSMA improved PSA ≥50% response rate (PSA50 RR), PSA progression-free survival (PFS), and radiographic PFS (rPFS) compared with cabazitaxel in mCRPC progressing after docetaxel [1]. In addition, it was hypothesised that a high PSMA expression would correlate to a better response to LuPSMA versus cabazitaxel, while a high FDG-positive tumour volume would correlate to a low response to either therapy. In other words, that PSMA PET would be a predictive biomarker and FDG PET a prognostic biomarker. Prof. Michael Hofman (Peter MacCallum Cancer Centre, Australia) presented the results of the analyses that explored this hypothesis [2].
Very high PSMA uptake on PSMA PET (SUVmean ≥10) was seen in 35/99 (35%) TheraP participants assigned to LuPSMA and 30/101 (30%) participants assigned to cabazitaxel. The odds of a response to LuPSMA versus cabazitaxel were significantly higher for men with SUVmean ≥10 compared with men with SUV <10 (OR 12.2 vs 2.2; P=0.03). In men with SUVmean ≥10, the PSA50 RR for LuPSMA versus cabazitaxel was 32/35 (91%) versus 14/30 (47%). In men with PSMA SUVmean <10, the PSA50 RR was 33/62 (52%) versus 23/71 (32%), respectively. The HR for PSA-PFS for LuPSMA versus cabazitaxel was 0.45 for SUVmean ≥10 versus 0.77 for SUVmean <10 (P=0.2).
High-volume metabolic disease on FDG PET (metabolic tumour volume [MTV] ≥200 mL) was seen in 30/99 (30%) TheraP participants assigned to LuPSMA and 30/101 (30%) participants assigned to cabazitaxel. The PSA50 RR in these men was 17/30 (57%) for LuPSMA versus 6/30 (20%) for cabazitaxel. In comparison, the PSA50 RR for men with MTV <200 mL on FDG PET was 48/69 (70%) for LuPSMA versus 31/71 (44%) for cabazitaxel. After accounting for treatment, the odds of a PSA50 response was lower among men with high MTV (OR 0.44; P=0.01).
Based on these results, Prof. Hofman concluded that in men with mCRPC, PSMA SUVmean ≥10 was predictive of a higher likelihood of favourable response to LuPSMA than cabazitaxel, and a high volume of disease on FDG PET was associated with a worse prognosis regardless of assigned treatment.
- Hofman MS et al. Lancet 2021;397:797-804.
- Buteau JP, et al. PSMA PET and FDG PET as predictors of response and prognosis in a randomized phase 2 trial of 177Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic, castration-resistant prostate cancer (mCRPC) progressing after docetaxel (TheraP ANZUP 1603). Abstract 10, ASCO GU 2022, 17–19 February.
Copyright ©2022 Medicom Medical Publishers
Posted on
Previous Article
« Artificial intelligence improves prediction of long-term outcomes Next Article
Radiohybrid PSMA PET imaging has favourable detection rate for prostate cancer recurrence »
« Artificial intelligence improves prediction of long-term outcomes Next Article
Radiohybrid PSMA PET imaging has favourable detection rate for prostate cancer recurrence »
Table of Contents: ASCO GU 2022
Featured articles
Prostate Cancer
First-line treatment with olaparib significantly improves PFS in mCRPC
First-line treatment with niraparib significantly improves PFS in HRR-mutated mCRPC
Darolutamide improves OS in mHSPC
Continued enzalutamide plus docetaxel offers clinical benefit for mCRPC patients who progress on enzalutamide
Radiohybrid PSMA PET imaging has favourable detection rate for prostate cancer recurrence
PSMA PET is a predictive biomarker in mCRPC progressing after docetaxel
Artificial intelligence improves prediction of long-term outcomes
Significant tumour response to neoadjuvant therapy in high-risk non-metastatic prostate cancer
Addition of abiraterone to ADT/docetaxel does not increase bone loss
Bavdegalutamide, a novel androgen receptor degrader, demonstrates clinical activity
Urothelial Carcinoma
No benefit of olaparib in previously untreated, platinum-ineligible, metastatic urothelial carcinoma
Rucaparib maintenance therapy extends PFS in platinum-responsive metastatic urothelial carcinoma
Positive efficacy and safety of N-803 plus BCG infusion in BCG-unresponsive NMIBC
Adding lenvatinib to pembrolizumab does not improve survival in advanced urothelial carcinoma
Maintenance niraparib fails to improve PFS in advanced urothelial cancer
First-line avelumab shows clinical activity in advanced urothelial carcinoma
Favourable pathologic response rate with neoadjuvant chemotherapy in high-risk upper tract urothelial carcinoma
Second-line nivolumab/ipilimumab boost improves ORR in metastatic urothelial carcinoma
Sacituzumab govitecan effective in platinum-refractory metastatic urothelial cancer
Neoadjuvant enfortumab vedotin promising in MIBC ineligible for cisplatin
Renal Cell Carcinoma
High-risk early RCC may benefit from neoadjuvant avelumab plus axitinib
DFS benefits with adjuvant pembrolizumab in RCC persist with longer follow-up
Biomarkers predict response to immune nivolumab (± ipilimumab) in advanced RCC
Combined nivolumab/axitinib treatment elicits good response in metastatic RCC
Folliculin mutations not associated with sporadic chromophobe RCC
Differential patterns of molecular alterations among sites of metastasis in RCC
Nivolumab monotherapy represents an alternative first-line treatment option for treatment-naïve mRCC
Penile & Testicular Cancer
HPV-positive and HPV-negative penile squamous cell carcinoma are molecularly distinct tumours
Atezolizumab does not improve survival in advanced penile cancer
Biomarkers to distinguish necrosis from teratoma before pcRPLND in testicular cancer
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com